nach oben

American Journal of Clinical Dermatology

Erschienen in:

16.11.2023 | Review Article

What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus

verfasst von: Georgia Biazus Soares, Joan Guitart, Gil Yosipovitch

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Cutaneous T-cell lymphomas are a heterogenous group of lymphomas that cause various skin manifestations. Severe pruritus occurs frequently in cutaneous T-cell lymphoma and negatively impacts patients’ quality of life. The pathophysiology of cutaneous T-cell lymphoma-associated itch is complex and involves various immune cells, inflammatory cytokines, and neuroimmune interactions. Treating cutaneous T-cell lymphoma pruritus can be challenging, and there have been few randomized controlled studies evaluating the use of antipruritic treatments in these patients. Systemic therapies targeting the disease have also been shown to have some antipruritic effects. Furthermore, although biologic therapy has revolutionized the treatment of other pruritic skin conditions, the use of biologics in cutaneous T-cell lymphoma remains controversial.

Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61.PubMedCrossRef

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-16.PubMedCrossRef

Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012;51(8):930–4.PubMedCrossRef

Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manag. 2013;45(1):114–9.CrossRef

Misery L. Pruritus in cutaneous T-cell lymphomas. In: Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Boca Raton (FL): CRC Press; 2014.

Ottevanger R, van Beugen S, Evers A, Willemze R, Vermeer M, Quint K. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):2377–87.PubMedPubMedCentralCrossRef

Gonzalez BR, Zain J, Rosen ST, Querfeld C. Tumor microenvironment in mycosis fungoides and Sézary syndrome. Curr Opin Oncol. 2016;28(1):88–96.CrossRef

Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in cutaneous T-cell lymphoma and its management. Dermatol Clin. 2018;36(3):245–58.PubMedCrossRef

Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021;30(6):804–10.PubMedCrossRef

10.

Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–7.PubMedCrossRef

11.

Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133(12):2783–5.PubMedCrossRef

12.

Möbs M, Gryzik S, Haidar A, Humme D, Beyer M, Vandersee S. Analysis of the IL-31 pathway in mycosis fungoides and Sézary syndrome. Arch Dermatol Res. 2015;307:479–85.PubMedCrossRef

13.

Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.PubMedPubMedCentralCrossRef

14.

Nattkemper LA, Martinez-Escala M-E, Gelman AB, Singer EM, Rook AH, Guitart J, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol. 2016;96(7):894–8.PubMedCrossRef

15.

Olszewska B, Żawrocki A, Gleń J, Lakomy J, Karczewska J, Zabłotna M, et al. Interleukin-31 is overexpressed in skin and serum in cutaneous T-cell lymphomas but does not correlate to pruritus. Postepy Dermatol Alergol. 2020;39(1):81–7.PubMedPubMedCentralCrossRef

16.

Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709–18.PubMedCrossRef

17.

Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma TH2 cytokines from malignant cells suppress TH1 in L-CTCL. Clin Cancer Res. 2013;19(14):3755–63.PubMedPubMedCentralCrossRef

18.

Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798–805.PubMedPubMedCentralCrossRef

19.

Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88(4):1383–9.PubMedCrossRef

20.

Suga H, Sugaya M, Miyagaki T, Ohmatsu H, Fujita H, Kagami S, et al. Association of nerve growth factor, chemokine (CC motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma. Acta Derm Venereol. 2013;93(2):144–9.PubMedCrossRef

21.

Hashimoto T, Mishra SK, Olivry T, Yosipovitch G. Periostin, an emerging player in itch sensation. J Invest Dermatol. 2021;141(10):2338–43.PubMedCrossRef

22.

Takahashi N, Sugaya M, Suga H, Oka T, Kawaguchi M, Miyagaki T, et al. Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma TSLP in cutaneous T-celllLymphoma. Cancer Res. 2016;76(21):6241–52.PubMedCrossRef

23.

Murota H, Lingli Y, Katayama I. Periostin in the pathogenesis of skin diseases. Cell Mol Life Sci. 2017;74:4321–8.PubMedCrossRef

24.

Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405–11.PubMedCrossRef

25.

Rüdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol. 2018;98(8):766–71.PubMedCrossRef

26.

Wong L-S, Yen Y-T, Lee C-H. The implications of pruritogens in the pathogenesis of atopic dermatitis. Int J Mol Sci. 2021;22(13):7227.PubMedPubMedCentralCrossRef

27.

Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53–62.PubMedCrossRef

28.

Shimizu K, Andoh T, Makino T, Yoshihisa Y, Mizawa M, Shimizu T. Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression. Eur J Dermatol. 2019;29:268–73.PubMedCrossRef

29.

Kural YB, Su O, Onsun N, Uras AR. Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T cell lymphoma. Int J Dermatol. 2010;49(4):390–5.PubMedCrossRef

30.

Fredholm S, Gjerdrum LMR, Willerslev-Olsen A, Petersen DL, Nielsen IØ, Kauczok C-S, et al. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res. 2014;34(10):5277–86.PubMed

31.

Günther C, Wozel G, Meurer M, Pfeiffer C. Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol. 2011;166(2):145–53.PubMedPubMedCentralCrossRef

32.

Rabenhorst A, Schlaak M, Heukamp LC, Förster A, Theurich S, von Bergwelt-Baildon M, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012;120(10):2042–54.PubMedCrossRef

33.

Eder J, Rogojanu R, Jerney W, Erhart F, Dohnal A, Kitzwögerer M, et al. Mast cells are abundant in primary cutaneous T-cell lymphomas: results from a computer-aided quantitative immunohistological study. PLoS ONE. 2016;11(11): e0163661.PubMedPubMedCentralCrossRef

34.

Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760–8.PubMedPubMedCentralCrossRef

35.

Terhorst-Molawi D, Lohse K, Ginter K, Puhl V, Metz M, Hu M, et al. Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: results of a pilot study. Front Immunol. 2022;13: 930979.PubMedPubMedCentralCrossRef

36.

Ui H, Andoh T, Lee J-B, Nojima H, Kuraishi Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol. 2006;530(1–2):172–8.PubMedCrossRef

37.

Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23(15):6176–80.PubMedPubMedCentralCrossRef

38.

Andoh T, Tsujii K, Kuraishi Y. Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis. Exp Dermatol. 2015;24(12):978–80.PubMedCrossRef

39.

Kim HS, Yosipovitch G. The skin microbiota and itch: is there a link? J Clin Med. 2020;9(4):1190.PubMedPubMedCentralCrossRef

40.

Lehman JS, Cook-Norris RH, Weed BR, Weenig RH, Gibson LE, Weaver AL, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010;146(6):607–13.PubMedCrossRef

41.

Matsui K, Kanai S, Ikuta M, Horikawa S. Mast cells stimulated with peptidoglycan from Staphylococcus aureus augment the development of Th1 cells. J Pharm Pharm Sci. 2018;21(1):296–304.PubMedCrossRef

42.

Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263–92.PubMedCrossRef

43.

Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375–90.PubMedCrossRef

44.

Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol. 2018;138(6):1311–7.PubMedCrossRef

45.

Tuzova M, Conniff T, Curiel-Lewandrowski C, Chaney K, Cruikshank W, Wolpowitz D. Absence of full-length neurokinin-1 receptor protein expression by cutaneous T cells: implications for substance P-mediated signaling in mycosis fungoides. Acta Derm Venereol. 2015;95(7):852–4.PubMed

46.

Booken N, Heck M, Nicolay J, Klemke C, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665–7.PubMed

47.

Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC Cancer. 2017;17:1–6.CrossRef

48.

Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42(8):1014–30.PubMedCrossRef

49.

Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134(8):949–54.PubMedCrossRef

50.

Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60(5):792–800.PubMedCrossRef

51.

Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–15.PubMedCrossRef

52.

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32.PubMedPubMedCentralCrossRef

53.

Zhong CS, Elmariah SB. Phototherapy for itch. Dermatol Clin. 2020;38(1):145–55.PubMedCrossRef

54.

Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27–58.PubMedCrossRef

55.

Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen–UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(3):335–41.PubMedPubMedCentralCrossRef

56.

Hooper MJ, Enriquez GL, Veon FL, LeWitt TM, Sweeney D, Green SJ, et al. Narrowband ultraviolet B response in cutaneous T-cell lymphoma is characterized by increased bacterial diversity and reduced Staphylococcus aureus and Staphylococcus lugdunensis. Front Immunol. 2022;13:1022093.PubMedPubMedCentralCrossRef

57.

Siakantaris MP, Tsirigotis P, Stavroyianni N, Argyropoulos KV, Girkas K, Pappa V, et al. Management of cutaneous T-cell lymphoma patients with extracorporeal photopheresis: the Hellenic experience. Transfus Apher Sci. 2012;46(2):189–93.PubMedCrossRef

58.

Arulogun S, Prince HM, Gambell P, Lade S, Ryan G, Eaton E, et al. Extracorporeal photopheresis for the treatment of Sezary syndrome using a novel treatment protocol. J Am Acad Dermatol. 2008;59(4):589–95.PubMedCrossRef

59.

Chen O, He Q, Han Q, Furutani K, Gu Y, Olexa M, et al. Mechanisms and treatments of neuropathic itch in a mouse model of lymphoma. J Clin Invest. 2023;133(4):e160807.

60.

Demierre M-F, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–4.PubMedCrossRef

61.

Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50(6):889–91.PubMedCrossRef

62.

Bigatà X, Sais G, Soler F. Severe chronic urticaria: response to mirtazapine. J Am Acad Dermatol. 2005;53(5):916–7.PubMedCrossRef

63.

Bromberg H, Chang Y, Craig D. Pruritic manifestation of peripheral T cell lymphoma effectively managed with mirtazapine: a case report. J Pain Palliat Care Pharmacother. 2020;34(3):153–4.PubMedCrossRef

64.

Maroñas-Jiménez L, Estrach T, Gallardo F, Pérez A, Andrés Borja H, Servitje O, et al. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. Br J Dermatol. 2018;178(4):e273–4.PubMedCrossRef

65.

Zic JA, Straka BT, McGirt LY, Nian H, Yu C, Brown NJ. Aprepitant for the treatment of pruritus in Sézary syndrome: a randomized crossover clinical trial. JAMA Dermatol. 2018;154(10):1221–2.PubMedPubMedCentralCrossRef

66.

Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63(4):680–8.PubMedCrossRef

67.

Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41(4):533–9.PubMed

68.

Brune A, Metze D, Luger T, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone: open, non-placebo controlled administration in 133 patients. Hautarzt. 2004;55:1130–6.PubMedCrossRef

69.

Khanna R, Kwon CD, Patel SP, Belzberg M, Williams KA, Khanna R, et al. Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: a case series from the Johns Hopkins Itch Clinic. J Am Acad Dermatol. 2020;83(5):1529–33.PubMedCrossRef

70.

Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54(3):527–31.PubMedCrossRef

71.

Labib A, Ju T, Lipman ZM, Yosipovitch G. Evaluating the effectiveness of intranasal butorphanol in reducing chronic itch. Acta Derm Venereol. 2022;102:adv00729-adv.CrossRef

72.

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.PubMedCrossRef

73.

Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.PubMed

74.

Morita A, Tateishi C, Muramatsu S, Kubo R, Yonezawa E, Kato H, et al. Efficacy and safety of bexarotene combined with photo (chemo) therapy for cutaneous T-cell lymphoma. J Dermatol. 2020;47(5):443–51.PubMedPubMedCentralCrossRef

75.

Ginsburg E, Hennessy K, Mhaskar R, Seminario-Vidal L. Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: a systematic review and meta-analysis. Dermatol Ther. 2022;35(5): e15418.PubMedCrossRef

76.

Field H, Gao L, Motwani P, Wong HK. Pruritus reduction with systemic anti-lymphoma treatments in patients with cutaneous T cell lymphoma: a narrative review. Dermatol Ther. 2016;6:579–95.CrossRef

77.

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–9.PubMedPubMedCentralCrossRef

78.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15.PubMedCrossRef

79.

Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia Lymphoma. 2012;53(8):1501–8.PubMedCrossRef

80.

Whittaker SJ, Demierre M-F, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–91.PubMedCrossRef

81.

Kim YH, Demierre M-F, Kim EJ, Lerner A, Rook AH, Duvic M, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leukemia Lymphoma. 2013;54(2):284–9.PubMedCrossRef

82.

Poligone B, Rubio-Gonzalez B, Querfeld C. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: a series of four cases. Dermatol Ther. 2019;32(2): e12804.PubMedPubMedCentralCrossRef

83.

Duvic M, Dummer R, Becker JC, Poulalhon N, Romero PO, Bernengo MG, et al. Panobinostat activity in both bexarotene-exposed and-naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386–94.PubMedCrossRef

84.

Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, et al. A Phase II trial of Belinostat (PXD 101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811–9.PubMedCrossRef

85.

Child F, Ortiz-Romero P, Alvarez R, Bagot M, Stadler R, Weichenthal M, et al. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016;175(1):80–8.PubMedCrossRef

86.

Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2021;192(4):683–96.PubMedCrossRef

87.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204.PubMedCrossRef

88.

Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, et al. Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leukemia. 2021;21(2):97–105.CrossRef

89.

Ottevanger R, van Beugen S, Evers AW, Willemze R, Vermeer MH, Quint KD. Quality of life in cutaneous T-cell lymphoma patients receiving mogamulizumab: important factors to consider. Cancers. 2022;15(1):32.PubMedPubMedCentralCrossRef

90.

Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11):4267–72.PubMedCrossRef

91.

Kennedy G, Seymour J, Wolf M, Januszewicz H, Davison J, McCormack C, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol. 2003;71(4):250–6.PubMedCrossRef

92.

De Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720–4.PubMedCrossRef

93.

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66.PubMedCrossRef

94.

Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, et al. Brentuximab vedotin for relapsed or refractory Sézary syndrome. JAMA Dermatol. 2021;157(3):317–21.PubMedCrossRef

95.

Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut J. Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol. 2005;74(2):169–71.PubMedCrossRef

96.

Oxberry S, Johnson M. Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma. Clin Oncol. 2006;18(1):86–7.CrossRef

97.

Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus. J Am Acad Dermatol. 2016;74(2):363–9.PubMedCrossRef

98.

Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol Ther. 2016;6:397–411.CrossRef

99.

Brightman L, Demierre M-F. Thalidomide in mycosis fungoides. J Am Acad Dermatol. 2005;52(6):1100–1.PubMedCrossRef

100.

Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123(8):1159–66.PubMedCrossRef

101.

Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869–76.PubMedCrossRef

102.

Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1331–7.PubMedCrossRef

103.

Mollanazar NK, Savage KT, Pousti BT, Jariwala N, Del Guzzo C, Haun P, et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. Cutis. 2020;106(3):131–2.PubMedCrossRef

104.

Lazaridou I, Ram-Wolff C, Bouaziz J-D, Bégon E, Battistella M, Rivet J, et al. Dupilumab treatment in two patients with cutaneous T-cell lymphomas. Acta Derm Venereol. 2020;100(16):1–2.CrossRef

105.

Schaefer L, Comfere N, Sokumbi O. Development of cutaneous T-cell lymphoma following biologic treatment: a systematic review. Am J Clin Dermatol. 2023;24(2):153–64.CrossRef

106.

Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–9.PubMedPubMedCentralCrossRef

107.

Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther. 2009;22(5):418–30.PubMedPubMedCentralCrossRef

108.

Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. Int J Dermatol. 2023;62(7):862–76.PubMedCrossRef

Titel: What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus
verfasst von: Georgia Biazus Soares
Joan Guitart
Gil Yosipovitch
Publikationsdatum: 16.11.2023
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 1/2024
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-023-00823-2

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Review of Teledermatology: Lessons Learned from the COVID-19 Pandemic

Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids

Acknowledgement to Referees

Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study